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CSince the North American Symptomatic Carotid End-
arterectomy Trial (NASCET) established the role of carotid
endarterectomy in the treatment of symptomatic carotid
stenosis,1 multiple randomized clinical trials, registries, and
observational studies have assessed the safety and efficacy of
several medical, interventional, and surgical treatments of
extracranial carotid disease.2 Standard methods of report-
ing the presenting symptomatology, comorbidities, lesion
characteristics, and techniques of interventions have be-
come imperative to assess specific outcomes. Because major
adverse events and complications after carotid interventions
are infrequent, multicenter trials, registries, or meta-
analyses of multiple individual studies are often necessary to
obtain adequate power to evaluate safety and efficacy of
carotid interventions. The complexity of the carotid le-
sions, adjacent anatomy, and patient comorbidities should
be accounted for during the reporting of carotid interven-
tions in order to accurately compare outcomes. As new
therapeutic techniques such as carotid artery stenting
(CAS) and advances in best medical treatment for vascular
disease have become available, it is equally important to
develop reporting standards that will allow accurate com-
*Carlos H. Timaran and James F. McKinsey contributed equally to this
article and are joint first authors.
From the Department of Surgery, University of Texas Southwestern
Medical School,a and Veterans Affairs North Texas Health Care System,
Dallasb; the Department of Vascular Surgery, Columbia University Col-
lege of Physicians and Surgeons, New Yorkc; the Division of Vascular
Therapy, Hawaii Permanente Medical Group, Honolulud; and the Divi-
sion of Peripheral Vascular Surgery, Edward Hines, Jr VA Hospital,
Chicago.e
Competition of interest: none.
Correspondence: James F. McKinsey, MD, Department of Vascular Sur-
gery, Columbia University, College of Physicians and Surgeons, New
York-Presbyterian Hospital, Columbia, New York, NY 10032 (e-mail:
jfm2111@columbia.edu).
Independent peer-review and oversight has been provided by members of the
SVS Document Oversight Committee (K. Wayne Johnston, MD (chair),
Enrico Ascher, MD, Jack L. Cronenwett, MD, R. Clement Darling, MD,
Lois A. Killewich, MD, PhD, Thomas F. Lindsay, MD, Gregorio A. Sicard,
MD).
J Vasc Surg 2011;53:1679-95
0741-5214/$36.00
Copyright © 2011 Published by Elsevier Inc. on behalf of the Society foro
Vascular Surgery.
doi:10.1016/j.jvs.2010.11.122arisons among the different trials and various treatment
odalities.
In 1988, the Ad Hoc Committee on Reporting
tandards of the Society for Vascular Surgery/Interna-
ional Society for Cardiovascular Surgery published sug-
ested reporting standards for studies dealing with ex-
racranial carotid disease.3 Because of the recent and
apid advancements in the treatment of carotid artery
isease, a revised version of the recommended standards
s warranted. This is particularly true as many uncertain-
ies and controversies about the management of carotid
rtery disease exist and should be addressed in future
andomized clinical trials and observational studies. As
ew data are generated from ongoing and future trials, it
s imperative to have uniform reporting standards that
ill allow meaningful meta-analyses according to differ-
nt patient, lesion, and procedural characteristics. Post-
arket surveillance registries will likely be mandated for
onventional risk patients undergoing carotid interven-
ions, as has been the case for patients at high risk for
arotid endarterectomy (CEA). Established reporting
tandards for these registries are also needed. A revised
nd recommended set of reported standards is presented
or the comparative analyses of data and outcomes re-
ated to the treatment of carotid artery disease. These
eporting standards were developed by a reporting com-
ittee appointed by the Society for Vascular Surgery and
epresent a consensus reached by this group.
LINICAL CLASSIFICATION AND
YMPTOMATIC STATUS
The American Heart Association published guide-
ines for the treatment of symptomatic carotid stenosis
ith CEA in 1995.4 Guidelines to clarify the indications
f surgery for asymptomatic carotid stenosis were pub-
ished in 1998.5 Both these documents were based on
evel I evidence provided by the largest clinical trials
omparing carotid endarterectomy versus best medical
anagement. These trials included the NASCET study,1
he European Carotid Surgery Trial (ECST),6 the Vet-
rans Affairs Symptomatic study,7 and the Asymptomatic
arotid Atherosclerosis Study.8 One major contribution
f these trials was the reporting of the perioperative
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June 20111680 Timaran et alstroke and death rates based on whether the patient was
symptomatic or asymptomatic. The resultant stroke and
death rates following carotid endarterectomy became the
standard of care to which other carotid interventions
were compared. Future reports assessing outcomes of
carotid interventions should therefore provide outcomes
based on symptomatic status, which needs to be clearly
established.
Symptomatic. Patients with carotid stenosis should
be considered symptomatic if they present with a history of
stroke, amaurosis fugax, or transient ischemic attacks (TIA)
involving the ipsilateral carotid territory that occurred
within 180 days of the initial assessment. A complete defi-
nition and discussion of these terms can be found in the
outcomes section.9,10 Although some controversy exists
regarding the duration of current ipsilateral carotid symp-
toms to define symptomatic status, the 180-day cutoff has
been used in most recent clinical trials dealing with carotid
artery disease, including the International Carotid Stenting
Study (ICSS),11 Stent-Supported Percutaneous Angio-
plasty of the Carotid Artery versus Endarterectomy
(SPACE),12 Angioplasty in Patients with Symptomatic Se-
vere Carotid Stenosis (EVA-3S),13 and Carotid Revascular-
ization Endarterectomy versus Stent Trial (CREST),14,15
in line with the definitions used in NASCET1 and ECST.6
Therefore, use of other time intervals to define symptom-
atic status is discouraged to gain uniformity in reporting.
Asymptomatic. Patients with carotid stenosis that do
notmeet the definition for symptomatic carotid stenosis are
considered asymptomatic. This includes patients with no
neurologic symptoms referable to the cerebral hemisphere
ipsilateral to the carotid stenosis or a history of previous
neurologic events without subsequent event within 180
days. Patients with prior symptoms referable only to the
hemisphere contralateral to the target vessel or symptoms
in either hemisphere occurring 180 days or longer prior to
the initial evaluation should also be considered asymptom-
atic. Moreover, patients with atypical or nonfocal neuro-
logic symptoms (ie, dizziness, confusion) or vertebrobasilar
symptoms should also be defined as asymptomatic from the
carotid artery standpoint.
CATEGORIZATION AND GRADING OF
COMORBID MEDICAL CONDITIONS
Clinical studies that evaluate carotid interventions,
particularly those that compare different treatment mo-
dalities, may be difficult to interpret when differences in
demographics, comorbid conditions, and perioperative
risk factors are not identified and characterized.16,17
Grading risk factors in severity with uniform definitions,
such as the Society for Vascular Surgery (SVS) 0 to 3
scoring scale, allows severity indexes to be calculated for
subgroup comparison.18 The following simplified grad-
ing system is adopted from the comorbid scoring system
currently used for reports dealing with lower extremity
ischemia (Table I).
In general, all conditions presumed to affect reported
outcomes should be recorded and reported in any study er trial. The comorbidities and scoring systems are
ainly intended to represent systemic factors that are
ikely to affect major morbidity and mortality associated
ith endovascular or surgical treatment of carotid le-
ions. Scoring all and each comorbid condition and risk
actors affecting outcome may not be necessary in all
nstances, but in a given report, it is important to specify
hose conditions and scores that pertain to the outcome
easures being investigated and reported, particularly
hose that affect an outcome for which a significant
ifference is claimed. Nevertheless, all of the SVS grad-
ng scales are included in this report for the advantage of
ollecting prospective data in a manner that facilitates
ater analysis (Table I).
Althoughmost risk factors are associated with anatomic
nd lesion characteristics, medical comorbid conditions
nd the adequacy of their treatment have also been identi-
ed as ominous predictors of periprocedural morbidity and
ortality after carotid interventions. For instance, octoge-
arians and uncontrolled diabetes, ie, when HbA1c 7%,
ave shown to be independent risk factors for neurologic
vents and/or 30-day operative mortality.19,20 In this re-
ard, the effects and potential increasing role of the current
edical treatment for vascular disease in the management
f patients with carotid artery disease needs to be system-
tically evaluated. Standardization and reporting of medical
herapies in light of the patient’s comorbidities in future
rials will be critical to determining the role of current best
edical therapy in preventing stroke in patients with ca-
otid stenosis.
Because carotid stenting with cerebral embolic protec-
ion is frequently used for the treatment of severe carotid
tenosis among high-risk patients, the presence of such
igh-risk categories,21-25 particularly those related to con-
omitant significant comorbidities, should always be spec-
fied and reported (Table II). This is particularly important
s recent observational studies challenge the adverse out-
omes seen after CEA among patients in these “high-risk”
ategories and demonstrate improved outcomes similar to
hose of low-risk patients.26-28 Future studies in which
urther risk stratification based on preintervention anatomy
nd comorbid conditions is assessed should report results of
arotid interventions according to “high-risk” criteria for
ach procedure.
IAGNOSTIC IMAGING STUDIES
Preprocedural evaluation of patients with carotid
rtery disease should include imaging studies to deter-
ine the degree of carotid stenosis and assess morpho-
ogic characteristics and location of carotid lesions. Ca-
otid duplex, computed tomography angiography
CTA), magnetic resonance angiography (MRA), and
igital subtraction angiography (DSA) are the most fre-
uent current methods of assessing carotid artery lesions.
TA, MRA, and DSA are also imaging studies capable of
ssessing vascular anatomy from the aortic arch to the
ntracranial circulation, which is particularly helpful for
valuating carotid and arch morphology of patients with
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Volume 53, Number 6 Timaran et al 1681carotid stenosis considered for CAS.29,30 The imaging
modalities used for preprocedural evaluation and their
findings should be reported.
Noninvasive vascular laboratory: Duplex ultra-
sound and transcranial Doppler. Duplex ultrasound is
usually the initial diagnostic method used in the evalua-
tion of carotid artery disease. Duplex ultrasound is inex-
pensive, convenient, and does not require radiation or
potentially nephrotoxic contrast medium. It is, however,
operator dependent and can be of limited value in se-
verely diseased or calcified vessels. Duplex findings may
be interpreted as abnormal when carotid velocities meet
previously validated criteria, such as NASCET or the
University of Washington modified criteria for non-
stented carotid arteries.31,32 If different velocity criteria
Table I. SVS medical comorbidity grading system
Categories/Grade
Diabetes
0 None
1 Adult onset, controlled by diet or oral agen
2 Adult onset, insulin-controlled
3 Juvenile onset
Tobacco use
0 None or none for last 10 years
1 None current, but smoked in last 10 years
2 Current (includes abstinence less than 1 ye
3 Current, greater than 1 pack/day
Hypertension
0 None (cutoff point, diastolic pressure usual
1 Controlled (cutoff point, diastolic pressure
2 Controlled with two drugs
3 Requires more than two drugs or is uncont
Hyperlipidemia
0 Cholesterol (low-density lipoprotein and to
1 Mild elevation, readily controllable by diet
2 Moderate elevation requiring strict dietary
3 Same as 2, but severe enough to require die
Cardiac status
0 Asymptomatic, with normal electrocardiog
1 Asymptomatic but with either remote myo
infarction by electrocardiogram, or fixed
2 Any one of the following: stable angina, no
thallium scan, significant silent ischemia
controlled ectopy or asymptomatic arrhy
compensated
3 Any one of the following: unstable angina,
(chronic/recurrent), poorly compensated
myocardial infarction within 6 months.
Renal status
0 No known renal disease, normal serum crea
1 Moderately elevated creatinine level, as hig
2 Creatinine level, 2.5 to 5.9 mg/dL
3 Creatinine level greater than 6.0 mg/dL, o
Pulmonary status
0 Asymptomatic, normal chest X-ray film, pu
1 Asymptomatic or mild dyspnea on exertion
65% to 80% of predicted
2 Between 1 and 3
3 Vital capacity less than 1.85 L, FEV1 less th
less than 50% of predicted, PCO2 greater
pulmonary hypertension.are used to determine the degree of stenosis, these ohould be validated at each laboratory using digital sub-
raction angiography as the reference standard. The sta-
us of validation and accreditation of the vascular labo-
atory performing the vascular evaluation should be
eported. For the highest degree of objectivity of the
uplex evaluation, a standard protocol to perform the
tudy should be developed and reported.33 Peak systolic
nd end diastolic velocities in the distal common carotid
rtery (CCA) and internal carotid artery (ICA) should be
arefully assessed and recorded. Similar evaluations of
reated or stented carotid arteries during follow-up sur-
eillance should be performed, with careful evaluation of
elocities and B-mode imaging at the proximal, middle,
nd distal portions of the stent. In cases of in-stent
estenosis, velocity and B-mode measurements at the site
ess than 1 pack/day
er than 90 mm Hg)
ly lower than 90 mm Hg) with single drug
.
nd triglyceride levels within normal limits for age
ol
and drug control.
l infarction by history (6 months), occult myocardial
t on dipyridamole thallium or similar scan
na but significant reversible perfusion defect on dipyridamole
of time) on Holter monitoring, ejection fraction 25% to 45%,
, history of congestive heart failure that is now well
tomatic or poorly controlled ectopy/arrhythmia
ecurrent congestive heart failure, ejection fraction less than 25%,
e level
.4 mg/dL
ialysis or with kidney transplant.
ary function tests within 20% of predicted
chronic parenchymal X-ray changes, pulmonary function tests
.2 L or less than 35% of predicted, maximal voluntary ventilation
45 mm Hg, supplemental oxygen use medically necessary, orts
ars), l
ly low
usual
rolled
tal) a
contr
tary
ram
cardia
defec
angi
(1%
thmia
symp
or r
tinin
h as 2
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June 20111682 Timaran et alreported. If a different methodology for determining the
degree of stenosis is used, it should be reported and
described in detail.
Transcranial Doppler (TCD) is a noninvasive ultra-
sound-based technique that is increasingly used for
periprocedural evaluation and monitoring of blood flow
velocities within the cerebral arterial circulation during
carotid interventions.34 The middle cerebral artery is the
vessel usually insonated with a 2 MHz pulsed signal
transmitted through the temporal bone. Gaseous or
solid microemboli within the middle cerebral artery can
be detected with TCD as high-intensity transient signals
(HITS), also known as cerebral microembolic signals
(MES).34,35 When TCD is used for monitoring carotid
interventions, the methods to detect microemboli
should be reported. In general, MES should be defined
as HITS with duration of 300 ms and amplitude that is
3 dB higher than the background blood flow signal.34
The total number of HITS detected throughout the
entire procedure and during different phases should be
reported, as appropriate.
Traditionally, TCD has been used during carotid end-
arterectomy to help assess the need for shunting during the
cross clamp phase36More recently, TCDhas also been used
to measure the intraoperative microembolic events during
CEA and CAS.35,37-39 The timing and methods of post-
procedural TCD monitoring should be reported, which is
particularly important because of the likely temporal vari-
ability in embolization during and after carotid interven-
tions. Because adverse neurologic events after CAS and
CEA are rare events in high volume practices, TCD moni-
toring and quantification of microembolizationmay also be
used as a surrogate end point in the evaluation of different
techniques and devices on cerebral embolization during
carotid interventions. Changes in flow velocities in the
Table II. Significant comorbidities that define high risk
for carotid endarterectomya
Clinically significant cardiac disease
Congestive heart failure (NYHA class III/IV)
Left ventricular ejection fraction 30%
Unstable angina (CCS class III or IV)
Two or more diseased coronary arteries with 70% stenosis
Recent myocardial infarction (24 hours and 4 weeks)
MI within 30 days and need carotid revascularization
Abnormal stress test
Need open heart surgery within 30 days
Severe pulmonary disease
Severe COPD defined as the need for home oxygen or PO2
60 on room air
Forced expiratory volume in 1 s (FEV1) 30% (predicted)
Dialysis-dependent renal failure
CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmo-
nary disease; MI, myocardial infarction; NYHA, New York Heart Associa-
tion.
aBased on conditions that were used to determine patients at high risk for
carotid endarterectomy in carotid stenting trials and registries, such as
ARCHER, CABERNET, CREATE, SAPPHIRE, and BEACH.cerebral circulation detected with TCD should also be aeported, particularly in cases of hyperperfusion and intra-
ranial hemorrhage after carotid interventions. TCD has, in
act, been proven useful in the prediction of these compli-
ations.40,41
Computed tomography and magnetic resonance
ngiography. With the increasing utilization of noninva-
ive imaging studies such as CTA andMRA prior to carotid
nterventions, standardization of the reporting of imaging
ndings is necessary.30 The specific examination protocols
hould be outlined and the technique for determining
easurements and the degree of stenosis specified in the
ethods section of the reports. Measurements of angio-
raphic carotid stenosis (percentage by diameter) in both
TA and MRA images should be standardized and the use
f NASCET methodology, as described below, is recom-
ended.1 The accuracy and correlation of CTA and MRA
ith duplex ultrasound evaluation or conventional angio-
raphic imaging, including intra- and interobserver vari-
bility, should be reported and discussed whenever possible
o validate the new imaging modalities relative to the gold
tandard, ie, digital subtraction angiography.29,30 Finally,
natomic assessment from the aortic arch to the intracranial
irculation andmorphologic characterization of the carotid
esions using CTA andMRA should be reported, including
hose instances in which the decision-making process has
een altered as these imaging modalities have demon-
trated to be useful for planning carotid interventions.29,30
he angiographic data should also be used to validate the
oninvasive data whenever possible.
Digital subtraction angiography. DSA remains the
old standard to determine the degree of carotid stenosis.1
he exact method of determining the angiographic degree
f stenosis should be described in detail. Although both the
ASCET1 and the ECST6methods have been widely used,
t is recommended to use NASCET methodology for most
eports. Indeed, most recent randomized clinical trials as-
essing outcomes of carotid interventions, including Euro-
ean trials, use the NASCET method.12,13 Only if near-
cclusion or “string-sign” is present, the NASCETmethod
hould be avoided as the degree of stenosis may be under-
stimated because of distal underfilling and near-collapse of
he internal carotid artery. NASCET criteria mandate that
he parallel tract of the internal carotid artery needs to be
sed for the reference vessel diameter, whereas the minimal
umen diameter within the carotid artery needs to be iden-
ified for the calculation of the percentage of diameter
tenosis [% diameter stenosis  (1  [minimal lumen
iameter/reference vessel diameter])  100] at baseline
nd after the carotid intervention. The most severe baseline
ercentage of diameter stenosis from two projections
hould be reported. Although patients may have been
ssigned to treatment based on previous noninvasive imag-
ng, it is imperative that validation and correlation of duplex
ltrasonography and, when available, CTA or MRA. Addi-
ionally, the degree of carotid stenosis should always be
etermined at the time of intervention when carotid stent-
ng is performed. Other angiographic findings, including
ortic anatomy, aortic arch type (types I, II, and III),42
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Volume 53, Number 6 Timaran et al 1683calcification and the degree of aortic thrombus, vascular
tortuosity, presence of plaque ulceration, and other lesion
characteristics should be described. In addition the angu-
lation, kinking, or coils within the inflow, bifurcation, or
outflow vessels of the carotid arterial system should be
defined.
Whether contralateral carotid angiography and intra-
cranial or cerebral angiography are required prior to or
during carotid interventions, particularly during CAS, is
controversial. When available, findings of these imaging
studies should be described and reported. Abnormal
findings in the intracranial circulation, specifically areas
of ipsilateral high-grade stenosis and the extent of con-
tralateral cross-filling, need to be documented and re-
ported.
Other imaging studies. Assessment of carotid plaque
composition is currently investigated as a means of treat-
ment stratification for patients with carotid artery stenosis
(carotid endarterectomy, carotid stenting, or medical treat-
ment). Symptomatic clinical presentation has, in fact, been
related to plaques with a large lipid and necrotic core size
and close location of the necrotic core relative to the fibrous
cap, which may result in increased risk of distal emboliza-
tion during carotid interventions.43-45 Moreover, nonvul-
nerable plaques (low lipid content) are more prone to
develop restenosis after intervention.46 A clinical need,
therefore, exists to develop methods to identify these
plaques prospectively before disruption and clinical expres-
sion of disease. Recent advances in imaging techniques
have shown the potential to determine carotid plaque com-
position and to identify these high-risk plaques. The char-
acteristics of the vulnerable plaque such as thin cap fibro-
atheroma and extensive necrotic or lipid core can be
identified with both invasive and noninvasive imaging tech-
niques. Noninvasive imaging modalities for identifying vul-
nerable plaque include ultrasound B-mode densitometry
and median gray-scale analysis, CT, angiography, and
MRI.47-50 Invasive modalities include intravascular MRI,
virtual histology intravascular ultrasound, coronary angios-
copy, coronary thermography, optical coherence tomogra-
phy, near-infrared spectroscopy, and palpography.51 Be-
cause the role of these imaging modalities has not been
established in the treatment of carotid stenosis, future
studies are needed to provide more information regarding
the natural history of vulnerable plaque to establish patient-
specific targeted therapy and to refine plaque stabilizing
strategies. Whenever these novel imaging modalities are
used, their findings should be reported. Moreover, out-
comes of carotid interventions should be assessed and
adjusted according to plaque composition and the presence
of vulnerable plaques, which, as indicated below, should be
taken into consideration to define the characteristics of
carotid lesions.
CAROTID LESION AND DISEASE
CLASSIFICATION
Specific characteristics of the carotid lesion are associ-
ated with a higher risk for adverse outcomes after carotid anterventions, including degree of stenosis, plaque mor-
hology and location, degree of calcification, tortuosity,
nd vascular angulations. These lesion characteristics
hould be systematically evaluated and reported. Although
recise classification methodology for reporting lesion
haracteristics affecting outcomes have not been defined
nd universally accepted, the following disease severity
cales and scores are based on specific risk factors for both
arotid endarterectomy and carotid stenting and may be
sed to determine and report outcomes based on disease
nd lesion severity. Grading carotid lesion characteristics in
everity with uniform definitions, as suggested in the scor-
ng scales below, allows severity to be assessed for subgroup
omparison even if the actual indexes or scores may not
lways be calculated.
isease and lesion severity scores
Disease and lesion severity score for carotid endar-
erectomy. Major risk factors for adverse outcomes after
arotid endarterectomy include symptomatic status, previ-
us carotid or extended neck surgery, neck irradiation,
ocation of carotid stenosis, lesion calcification, and plaque
orphology. To categorize the grades of severity of carotid
rtery disease prior to CEA, a 0 to 3 scale corresponding to
bsent, mild, moderate, and severe can be obtained for each
f the risk factors, which may allow the calculation of a
lobal disease severity score for the carotid lesion (Table
II). As mentioned above, symptomatic status is the most
mportant predictor of major adverse events after any ca-
otid intervention.2 Indeed, current guidelines define dif-
erent thresholds of stroke and death after carotid endarter-
ctomy according to the presence of symptoms.4,5 Previous
arotid or extended neck surgery has been shown to signif-
cantly increase the complexity of surgical intervention
esulting in a higher risk of cranial nerve injury as well as
ore challenging dissection when compared to de novo
pen carotid intervention.16 Radiation into the cervical
egion has been shown to have various effects on the extent
f fibrosis scarring as well as injury to the carotid artery
tself. Chronologically, more distant radiation may have
nvolved a larger field dose, thereby affecting all tissue
ithin the surgical region.16 Recent advances in radiation
herapy tend to focus the radiation on the specific lesion
eep to the skin and decrease radiation doses to the sur-
ounding uninvolved tissue. Contralateral carotid stenosis
r occlusion has traditionally been considered a predic-
or for adverse outcome after CEA according to
ASCET data.1 The location of the lesion relative to the
arotid bifurcation and the base of the skull are anatomic
ariables that may increase the complexity of carotid
ndarterectomy.16 A focal bifurcation lesion in the mid-
eck may decrease the complexity of the surgical proce-
ure, whereas a very long or distal lesion near the base of
he skull or a low lesion behind the clavicle may add
ramatically to the complexity of a carotid endarterec-
omy and increase the risk of complications. A near-
cclusive carotid lesion or “string sign” may be associ-
ted with a high-grade carotid stenosis extending from
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June 20111684 Timaran et althe origin of the internal carotid artery to the base of the
skull, which may affect initial technical success, long-
term patency, and the risk for periprocedural stroke.52
Finally, recent studies have revealed that carotid plaque
morphology, particularly the presence of extensive areas
of calcification and necrotic or lipid core, may actually be
a predictor of both preprocedural symptomatic status
and periprocedural complications.45
CAS disease and lesion severity score. Specific risk
factors affecting outcomes after CAS have been identi-
fied and are frequently separate and distinct from those
for carotid endarterectomy.17,53 Carotid artery disease
and lesion severity for each type of intervention may
therefore need to be reported to assess periprocedural
risk. The main predictors for adverse outcomes associ-
ated with CAS include symptomatic status, patient age,
aortic arch anatomy, angulation and tortuosity of the
common and internal carotid arteries, lesion length and
calcification, and plaque morphology.17 Contrary to ca-
rotid endarterectomy, age has been found to be an
independent predictor for periprocedural stroke and
death after CAS, particularly when filters are used for
cerebral embolic protection.19 Regarding the aortic
arch, not only the degree of elongation, tortuosity, or
the location and angulation of the take-off of the great
vessels are important for the safe selective catheterization
of the common carotid artery, but also the extent of
Table III. Definition, grading, and categorization of caro
Attribute Absent Mild 
A. All carotid
interventions
Symptomatic status Asymptomatic Amaurosis fugax
Lesion calcification None Mild non-circum
scattered
Lesion length 15 mm 15 mm but m
one lesion
Carotid plaque
morphology
Fibrous plaque/
web
Mild calcificatio
B. Carotid
endarterectomy
Previous ipsilateral
carotid or extended
neck surgery
No
Previous neck radiation No Neck supple
Lesion location Lower or mid-
neck
Abnormal low b
clavicle
Contralateral carotid
stenosis/occlusion
Normal or
60%
60%-80
C. Carotid stenting
Patient age (years) 70 70-75
Aortic arch type I II
Aortic thrombus None Minimal or abse
Carotid angulation and
tortuosity
None Mild angulation
aCumulative Carotid Disease Severity Score may be calculated by adding P
carotid stenting. TIA, transient ischemic attack.mural thrombus and arterial wall plaque, which may Oncrease the risk of ipsilateral and contralateral emboli-
ation.17,29 The angulation and tortuosity of the com-
on carotid and internal carotid arteries have significant
mpact on the safe advancement and placement of guid-
ng catheters or sheaths as well as the safe deployment of
mbolic protection devices. Arch angulation and tortu-
sity of both common and distal internal carotid arteries
an be assessed by calculating a tortuosity index, ie, the
um of all angles diverging from the ideal straight axis
rom the arch.54 Proximal and distal TIs can be measured
rom the arch to the carotid lesion and from the lesion to
he point of embolic protection device (EPD) deploy-
ent, respectively. Severe stenosis or occlusion of the
psilateral external carotid artery can also cause difficul-
ies for the advancement of the delivery system into the
ommon carotid artery, as there is no an anchoring site
or the required supportive stiff wire.17 Extensive calci-
cation and concentric calcification may prevent ade-
uate stent deployment and expansion and may be con-
idered a contraindication for CAS. Lesion location and
ength may also influence the technical success of CAS.53
esion length should be defined using the American
eart Association/American College of Cardiology clas-
ification for coronary lesions as modified by Ellis, et al,55
n which the distance from the distinct proximal to distal
houlder of the lesion is assessed in the projection that
est elongates the portion of stenosis that is 50%.
tery disease and lesion severity for carotid interventionsa
Moderate  2 Severe  3
TIA/minor stroke Major stroke
tial Moderate multifocal Severe circumferential
an 15 mm or if 2 stents
are required
More than one lesion
15 mm
Mixed fibrous/ulcerative
plaques/thin cap
Multiple large calcification
or lipid/necrotic cores
Yes
Neck firm Neck hard
the Midneck extending to C2 Upper neck (C2 or
higher/string sign)
80% Occlusion
75-80 80
II with reverse angulation
of the target vessel
III
Moderate scattered Severe circumferential
along greater curve
° Moderate (60°) or
multiple angulations
Severe (coil or 90° kink)
A  PART B for carotid endarterectomy and/or PART A  PART C fortid ar
1
feren
ore th
n
elow
%
nt
60stial involvement has been associated with adverse
t
p
d
u
t
c
a
O
r
c
c
s
t
c
e
b
p
n
h
p
c
a
m
V
a
d
p
t
i
t
f
a
T
p
M
M
M
M
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 6 Timaran et al 1685outcomes after CAS and should be indicated by a steno-
sis that is ostially centered, ie, when the maximal point of
stenosis is located at the internal carotid ostium.53 Fi-
nally, plaque morphology and composition may be asso-
ciated with an increased emboligenic potential that may
result in major adverse events that can occur during and
after the procedure (Table III).45
CATEGORIZATION OF CAROTID
INTERVENTIONS
Carotid endarterectomy. The type of anesthesia used
should be reported.16 Whether routine, selective, or no
shunting is used, the specific modality of cerebral perfusion
or neurologic monitoring applied during the procedure
should be reported and correlated with complications and
outcomes.
A brief description of the surgical technique should
be provided in the Methods section, particularly indicat-
ing the types of closure (primary vs patch), patch (vein vs
prosthetic or biologic material), and endarterectomy
technique (standard arteriotomy and plaque elevation vs
eversion with or without resection). Dissection and mo-
bilization of the common carotid, internal carotid, and
external carotid arteries should be meticulous so the
adjacent cranial nerves are left intact. Whenever the
dissection is difficult or impaired by any factors, it should
be reported. The carotid bifurcation should not be mo-
bilized, according to many authors, until the carotid
arteries have been clamped to avoid the potential of
Table IV. Recommendations for reporting carotid
stenting procedural data
Preprocedural antiplatelet therapy
Aspirin  clopidogrel
Aspirin  ticlopidine
Use of GP IIb/IIIa antagonists
Anticoagulation
Heparin
Thrombin inhibitors
Approach/access site
Transfemoral
Alternative access sites
Radial or brachial
Direct carotid
Percutaneous
Open exposure
Sheath and/or guiding catheter placement technique
Over-the-wire
Telescoping
Coronary
Type of embolic protection devices
Occlusive
Flow-reversal
Distal balloon occlusion
Nonocclusive (filters)
Eccentric
Concentric
Stent design and configuration
Open-cell vs closed-cell vs hybrid
Tapered vs nontaperedembolization of atherosclerotic plaque or thrombus in bhe area of the critical stenosis. This is particularly im-
ortant in those patients with recent symptoms. Any
eviations from this standard technique should be doc-
mented. If unusual or adjuvant techniques are utilized,
hese should be described in detail. The type of peripro-
edural antiplatelet therapy and anticoagulation as well
s reversal of anticoagulation should be documented.
ther important procedural variables that should be
eported include procedure time, time of carotid cross-
lamping, blood loss, intraoperative hemodynamic
hanges and the routine or selective use of intra-arterial
hunts. Finally, the immediate neurologic assessment of
he patient upon completion of the procedure should be
arefully documented, as should a repeat neurologic
xamination within 24 hours. The initial assessment may
e performed by the operating physician, but ideally, and
articularly in randomized clinical trials, a secondary
eurologic assessment should be performed within 24
ours by a stroke specialist.
CAS. CAS techniques and procedures should be re-
orted in sufficient detail to determine the magnitude and
omplexity of CAS, including all the additional maneuvers
nd procedures necessary to obtain technical success and
aintain a clinically durable outcome (Tables IV, V, and
I). The type and duration of antiplatelet therapy and
dministration, ie, preprocedural administration for 3 to 4
ays versus loading dose at least 4 hours prior to the
rocedure, should be reported. The duration of antiplatelet
herapy after the procedure should also be specified. Defin-
ng the type of anticoagulation used for CAS is also impor-
ant. Heparin and direct thrombin inhibitors are the pre-
erred anticoagulation regimens. Both are usually
dministered to maintain the activated clotting time (ACT)
able V. Periprocedural adjunctive maneuvers: Planned
rocedures
anagement of concomitant iliac, innominate, common carotid,
and internal carotid artery occlusive disease
Balloon dilatation
Stent placement
“Sizing” with arterial dilator
anagement of access site
Percutaneous arterial access site closure/type of closure device
Modified access sites
Radial or brachial
Direct carotid
Percutaneous
Open exposure
anagement of arterial tortuosity
Use of telescoping or coronary techniques
Use of buddy wire
Brachiocephalic-femoral wire
Direct or indirect manual deformation of artery
anagement of hemodynamic changes, vascular spasm, or recoil
Administration of anticholinergics
Administration of vasopressors
Use of temporary pacing
Use of intra-aortic balloon counterpulsation
Intra-arterial administration of vasodilatorsetween 250 and 300 seconds. ACT values should be
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sufficient or excessive anticoagulation are reported. The use
of other adjuvant pharmacologic therapies, such as GP
IIb/IIIa antagonists during CAS to reduce the microcircu-
latory impact of distal embolization, and indications for use
should also be specified.
The specific site of access should be reported. Al-
though percutaneous and open cervical approaches have
occasionally been used for CAS, the transfemoral, trans-
brachial, and transradial routes are more frequently used.
The influence of the access site on CAS outcomes may be
related to the avoidance of unfavorable arch anatomy and
catheter manipulations, which emphasize the impor-
tance of reporting the vascular approach used for CAS
and its indication. Specific complications related to a
cervical or upper extremity carotid access need to be
described, particularly the frequency of dissection,
thrombosis, and hematoma formation as well as associ-
ated neurapraxia. The type of technique used to intro-
duce the sheath or guiding catheter into the common
carotid artery needs to be specified as well as the fre-
quency in which alternative techniques are used.17 The
type of diagnostic and guiding catheters, guidewires, and
sheaths used during CAS should also be specified.
The specific type of EPD used should be reported
(Table IV). Because these devices have intrinsic advan-
tages and disadvantages with specific technical fea-
tures,17 it is imperative to report the type and design of
EPDs used in terms of the features of the treated carotid
lesions and anatomy. The use of EPDs is not exempted
from complications and may increase the inherent risks
to the procedure. Therefore, it is necessary to describe all
intrinsic problems associated with their use, including
difficulties in advancing and deploying the device, effec-
tiveness in embolic protection, EPD induced vessel
spasm or injury, and difficulties in recapturing and with-
Table VI. Periprocedural adjunctive maneuvers:
Unplanned procedures
Management of vascular access injuries or perforation of iliac/
aortic or carotid arteries
Open repair
Endovascular repair
Management of obstructed blood flow to distal carotid artery
and/or cerebrovascular perfusion with or without
periprocedural stroke
Thrombolysis
Systemic administration of GP IIb/IIIa antagonists
Mechanical thrombectomy with or without thrombolysis
Balloon dilatation
Carotid endarterectomy and/or open thrombectomy
Carotid patch repair or bypass graft
Maneuvers designed to address EPD or stent malfunctioning
Use of additional stents
Use of snares to remove detached EPD or embolized stent
Stent deployment at an unintended site
Conversion from endovascular to open repair
EPD, Embolic protection device.drawing of the device. When several EPDs are at- sempted, the specific causes of failure should be de-
cribed. Abnormal findings of periprocedural angio-
rams related to deployment or withdrawal of EPDs
eed to be described. This is particularly important when
arge amounts of emboli may saturate EPDs of the filter
ype, which may be suggested angiographically by re-
uced or absent flow through the ICA. Adjuvant maneu-
ers to remove the filter, such as partial capture and
spiration prior to collapse of the filter should be re-
orted (Tables V and VI). The frequency of flow reversal
r balloon occlusion intolerance and methods to address
t need to be reported when these EPDs are used.
The frequency of predilatation versus primary stent-
ng should also be specified. Although primary stenting
f carotid lesions may be performed, predilatation is
enerally required for severely stenotic carotid lesions.
he size of the balloons used for predilatation should be
entioned. The frequency of postdilatation should be
pecified indicating the balloon size used. The degree of
esidual stenosis should be detailed taking into account
hat a 10% to 30% residual stenosis is considered accept-
ble. Since postdilatation of the stent may be an impor-
ant emboligenic part of the procedure, any associated
eurologic or hemodynamic adverse events should be
eported noting that they specifically occur during this
hase of the intervention.
Different types of stents and stent designs are avail-
ble for CAS (Table IV). Stents characteristics, including
onfiguration, material, diameter and length, number,
nd the specific type of stents used should be described
or all procedures. Depending on the density of the
ridges between the different rings after deployment,
arotid stents can be classified into stents with a closed-
ell or an open-cell configuration. Because the size of the
nterstices and struts of different stents vary, it may also
e advisable to report the stent free-cell area, particularly
hen multiple stents are used, when appropriate for a
pecific study. The use and specific configuration of
hybrid” stent design, ie, with segments of open- and
losed-cell areas within the same stent, should also be
pecified. The influence of stent design and free-cell area
n CAS outcomes has yet to be established. Thus, future
nvestigations may lead to further refinement of the
mportance of stent design on outcomes after CAS.
eports should also state whether the stents fully or
artially cover the ICA, CCA, or both. Difficulties in
tent placement should be reported. The need of addi-
ional stents to exclude the lesion length and possible
easons should be defined. Defining other stent deploy-
ent complications related to tortuosity or kinking
bove the lesion in terms of the type of stent used is
ritical. Significant angulation of the proximal or distal
nd of the stent need to be specified as stent placement
ay worsen distal tortuosity or kinking by reducing the
rterial compliance as the kink is displaced upward to the
kull base where it may be more difficult to treat.
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DEFINITIONS
The primary objective of the treatment of carotid
stenosis is the reduction of the risk of stroke and death.
Therefore, by definition, the primary outcome criteria for
any carotid intervention include the prevention of: (1) all
periprocedural strokes and death; (2) subsequent ipsilat-
eral stroke; and (3) stroke or death that may result from
primary or secondary treatment. Most current observa-
tional studies, registries, and clinical trials also include
myocardial infarction as a primary end point, which is
particularly important when reporting outcomes of ca-
rotid procedures among high-risk patients. Whether sin-
gle or composite end points are used, it should be
specified what events are included and the time interval
in relation to the procedure in which these may occur.
The primary end points for most reports should include
any stroke, myocardial infarction, and death during the
30-day periprocedural period, and stroke ipsilateral to
the procedure thereafter. Because carotid interventions
do not always result in persistent benefit, surrogate
markers that suggest a continuing or increasing risk of
stroke, such as in-stent restenosis, restenosis after CEA,
vascular or stent patency, and target lesion revasculariza-
tion, although designated as secondary outcome criteria,
play a critical role in the overall assessment of the effec-
tiveness of any carotid treatment strategies. The impor-
tance of reporting accepted and uniform measures of
clinical success that combines the most significant of
primary and secondary outcome criteria, which reflect
the goals of any treatment method, cannot be overem-
phasized. The definition and reporting of clinical success
and associated outcome criteria that imply clinical effec-
tiveness of carotid interventions are included below.
Definition of success. Defining the outcomes and
success of carotid interventions remains dependent on a
consideration of both clinical and imaging criteria within
the context of the historic standard established by ca-
rotid endarterectomy. In this regard, a similar result can
only be accomplished with a stent, if complete exclusion
of the lesion is achieved with subsequent stroke preven-
tion.
Definition of technical success. Technical success re-
lates to periprocedural events that occur from the initia-
tion of the procedure and extend through the first 24-
hour postoperative period. Primary technical success is
usually defined on an intent-to-treat basis, particularly in
clinical trials, and requires the successful exclusion of the
carotid plaque by surgical or interventional means. Tech-
nical success should also include the outcomes and com-
plications of preoperative carotid angiograms whenever
these imaging studies are obtained prior to the carotid
intervention. For carotid endarterectomy, primary tech-
nical success implies a successful removal of the carotid
plaque and closure of the artery with or without patch
and less than a 30% residual stenosis. For carotid stent-
ing, the introduction and deployment of the EPD and she carotid stent in the absence of stroke, myocardial
nfarction, death, surgical conversion, or vascular ob-
truction constitutes primary technical success, which
hus implies the following qualifying details:
. successful access to the carotid arterial system using a
remote site (ie, the femoral or brachiocephalic arteries
with or without use of a percutaneous or open ap-
proaches to access these arteries);
. successful deployment and placement of the EPD and
the carotid stent excluding the entire length of the
carotid lesion;
. patent carotid stent with normal flow and without sig-
nificant twist, kinks, or obstruction (30% luminal ste-
nosis or a pressure gradient10 mmHg) by intraoper-
ative measurements; and
. successful removal of the EPD without evidence of
EPD-related vascular injuries.
rimary technical success can include the use of additional
omponents, stents or angioplasty, and adjunctive surgical
rocedures. However, if unplanned endovascular or surgi-
al procedures are needed to maintain or restore patency,
hen the procedure is not primarily successful and the terms
ssisted primary or secondary technical success, respectively,
hould be used. Conversely, for carotid endarterectomy,
he use of unplanned surgical or endovascular interven-
ions, such as revision of the anastomosis or additional
ngioplasty and stenting, would constitute primary or sec-
ndary technical success, respectively.
Secondary end points should be reported, such as pro-
edure time, blood loss, blood transfusion, clamping and
hunting time, fluoroscopy time, contrast load, recovery
ime, range and average number of days in an intensive care
nit, and hospital length of stay. However, these parame-
ers do not enter into the consideration of technical success
ates.
Definition of peri- and postprocedural clinical
uccess. Periprocedural clinical success should be re-
orted on an intent-to-treat basis and requires successful
ompletion of the carotid endarterectomy and vascular
losure or deployment of the carotid stent at the in-
ended location without stroke, myocardial infarction or
eath, vascular injury, or conversion to endovascular or
pen repair, respectively. Moreover, the presence of
esidual stenosis of 30% or more by diameter and stent or
PD malfunctioning classify a case as a clinical failure.
eriprocedural, or 30-day clinical success encompasses
0-day data.
Outcomes that represent clinical success rates should
e reported as long as the data are statistically valid for
he time period in question. Specifically, the standard
eviation of life table or Kaplan-Meier estimates should
ot exceed 10%. Temporal duration of clinical success
hould be reported for all carotid interventions. Short-
erm clinical success includes outcome measures reported
ithin a 30-day to 1-year time frame. Midterm clinical
uccess refers to all outcome measures that are statistically
ignificant up to 5 years after the carotid intervention.
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that are statistically significant beyond 5 years. Clinical
success for carotid interventions encompass a series of
generic vascular outcome variables that include primary,
assisted primary, and secondary patency that are related
to the treated carotid artery and, more importantly,
specific outcome variables that include freedom from
ipsilateral stroke, restenosis, target lesion revasculariza-
tion, and patient survival.
For treated carotid arteries, primary patency refers to
patency that is obtained without the need for an additional
or secondary surgical or endovascular procedure. Assisted
primary patency is patency achieved with the use of an
additional or secondary endovascular procedure as long as
occlusion of the primary treated site has not occurred.
Secondary patency is patency obtained with the use of an
additional or secondary surgical procedure once occlusion
occurs (eg, the performance of carotid interposition bypass
grafting). Because carotid revascularization once occlusion
occurs is very rarely performed, secondary patency may not
need to be reported. Conversely, clinical failure includes a
failure to complete a carotid endarterectomy or deploy the
stent at the intended location, carotid or stent thrombosis
or infection, restenosis, conversion to open or endovascular
repair, or death as a result of carotid stenosis or carotid
artery-related treatment. Moreover, the presence of pseu-
doaneurysm or a failure of patch or stent integrity classifies
a case as a clinical failure.
Although target lesion revascularization (TLR) has
been considered the best clinical surrogate for angiographic
restenosis for percutaneous coronary interventions because
repeat coronary angiography is not performed routinely,
other clinical end points such as patency and freedom from
ipsilateral stroke or significant restenosis are essential and
preferable to determine safety and effectiveness of any
carotid intervention as objective criteria of ongoing clinical
success should always be available. Moreover, TLR does
not always contribute to the assessment of clinical treat-
ment failures because it is not always driven by clinical
evidence of symptoms and may not be affected in cases of
asymptomatic carotid artery or stent occlusion or in asymp-
tomatic high-risk patients, in which reinterventions may
not be indicated. If TLR is reported, which is not recom-
mended, any surgical or percutaneous revascularization
procedure involving the original target lesion site should be
reported as TLR. Repeat balloon angioplasty, stenting,
endarterectomy, or any other open vascular reconstruction
of the treated lesion should be considered TLR. Con-
versely, TLR should not include staged procedures involv-
ing other lesions in the same vascular territory that do not
involve the specific initial carotid artery lesion such as
angioplasty or bypass grafting procedure of proximal or
distal lesions.
Any narrowing of the treated segment occurring
after 30 days of the carotid intervention should be re-
ported as restenosis. Assessments of patency and degree of
restenosis at the treated site during follow-up should be
performed and reported. Surveillance of carotid arteries after intervention (either CEA or CAS) is important
ecause early detection of restenosis can allow for rein-
ervention prior to progression to occlusion or stroke.31
uplex ultrasound has been shown to be an efficacious
nd cost-effective surveillance tool for restenosis after
EA, and several studies have shown that it is likely
dequate for use in surveillance after CAS.31,56,57 How-
ver, these same studies have shown that the velocities
btained by duplex ultrasound after CAS are elevated for
given degree of stenosis, thus indicating that to accu-
ately detect in-stent restenosis, duplex criteria should be
evised for stented carotid arteries.58,59 Moreover, be-
ause significant difference in velocity criteria for reste-
osis has been reported after carotid interventions, it is
mperative for each vascular laboratory to develop its
wn criteria for duplex ultrasound for detecting carotid
estenosis using carotid angiography as the gold stan-
ard. Once validated, such criteria should be reported in
etail in the Methods section of the report. Changes in
verage percent stenosis at follow-up should be reported
sing statistical adjustment (by analysis of covariance)
or observed duplex velocity characteristics at 1 month.
djustment for the 1-month ultrasound is suggested
ecause increased flow at this time point is likely to be
ssociated with hemodynamic disturbances associated
ith the type of patch or stent rather than true resteno-
is.60,61 Because optimal methods to detect restenosis
ave not been completly established, future studies
hould assess specific anatomic, lesion, patch, stent, and
ther patient characteristics that could affect the detec-
ion and incidence of restenosis. Moreover, duplex, CT,
r MRI characterization of the restenotic plaque should
e reported when possible.
Although the actual degree of restenosis may be needed
or assessments of differences between carotid interven-
ions, the proportion of patients with both moderate
50%) and severe (80%) restenosis after carotid inter-
entions may be clinically and hemodynamically more im-
ortant. Moreover, clinically significant restenosis after
rior carotid intervention, ie, restenosis 50% for symp-
omatic patients and 80% restenosis for asymptomatic
atients, particularly when additional treatment is required,
hould always be reported. In such circumstances, angio-
raphic confirmation of the degree of restenosis should
referably be obtained.
Longitudinal reporting of clinical outcome measures.
he following parameters are recommended for inclu-
ion in any comprehensive report of carotid interven-
ions: patient survival; freedom from ipsilateral stroke;
revalence of ipsilateral stroke and carotid stenosis-re-
ated death; freedom from restenosis; treated carotid
rtery and stent patency; and technical and clinical suc-
ess rates.
Life tables or Kaplan-Meier curves should be calculated
or presentation of patient survival and freedom from ipsi-
ateral stroke, maintenance of clinical success, and freedom
rom restenosis. Treated carotid artery and stent patency
nd target lesion revascularization should be reported in life
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Volume 53, Number 6 Timaran et al 1689table or Kaplan-Meier format as primary, assisted primary,
or secondary depending on the use of additional endovas-
cular or surgical procedures.
Changes in cognitive function may occur as a result
of carotid interventions. Therefore, for those patients in
whom mental and cognitive function are assessed, a
separate analysis should be reported with the possible
risk factors and longitudinal changes in neurocognitive
function. A battery of neuropsychometric tests should be
used, including tests that assess verbal fluency and visu-
ospatial organization, which provide insight into the
functioning of the dominant and nondominant hemi-
spheres, respectively.62,63
Periprocedural adjunctive maneuvers. A principal
procedure is one that the surgeon or interventionalist be-
lieves to contribute most to the treatment of the carotid
lesion, such as carotid endarterectomy or stent placement.
An adjunctive procedure is any other procedure that is
designed to augment the effects of the principal procedure,
such as proximal angioplasty or stenting of a proximal
common carotid artery lesion. Such procedures may occur
in the periprocedural or postprocedural periods and should
be designated in like manner. An ancillary procedure is one
that does not contribute to the overall treatment of the
carotid stenosis, such as the simultaneous endovascular
treatment of subclavian artery stenosis. Primary procedures
refer to all interventions performed at the time of initial
CEA or CAS procedures. Secondary procedures include all
open or endovascular interventions performed at a later
date.
It is recommended that periprocedural adjunctive ma-
neuvers be classified as planned procedures or unplanned
procedures. Planned procedures comprise techniques that
are part of a preformulated procedural strategy, and un-
planned procedures are necessary for management of unin-
tended complications or an otherwise unsatisfactory
outcome. Categorization of perioperative adjunctive pro-
cedures is based on a consideration of unique sets of com-
mon objectives that are most often related to treatment of
concomitant arterial occlusive disease to facilitate access or
a prophylactic intervention to reduce the likelihood of
distal occlusion, such as with tortuous or redundant inter-
nal carotid arteries. For example, the treatment of concom-
itant arterial occlusive disease may be necessary to improve
access through the iliac arteries or to allow the treatment of
proximal common carotid or innominate artery occlusive
disease, which may be mandatory to complete the principal
procedure. Categorization schemes for planned and un-
planned periprocedural maneuvers are provided in Tables V
and VI, respectively.
Postprocedural adjunctive maneuvers. Postprocedural
interventions should be categorized with respect to treat-
ment objectives, including vascular access management,
stroke, and recurrent or in-stent restenosis. In addition to
reporting procedures used in the management of vascular
access obstruction, outcomes should be described in accor-
dance with published standards for reports dealing with lower extremity ischemia.18 A categorization scheme for
ostprocedural maneuvers is provided in Table VII.
Conversion to carotid endarterectomy or open re-
air and conversion to carotid stenting. Conversion
rom carotid stenting to endarterectomy or vice versa may
e required either at the original operation or within 30
ays (primary conversion) or on a subsequent occasion
secondary conversion). Secondary conversion should also
e classified as urgent or elective. Details of conversion
hould be reported, including indication, difficulties in
ascular access, inability to tack a distal plaque, and other
elevant operative information. Additional imaging studies,
uch as angiography and duplex or intravascular ultra-
ound, may be conducted in the angiography suite or the
perating room to assist in a final determination of CEA or
AS suitability for a particular lesion. Therefore, intent-to-
reat should be considered initiated by anymaneuver directed
t treating the carotid lesion with a surgical or endovascular
pproach that follows the completion of the definitive carotid
maging study, ie, duplex ultrasound, CTA, MRA, or
eriprocedural DSA.
Comparing the clinical success of carotid endarter-
ctomy and stenting. Investigations that compare ca-
otid endarterectomy and stenting should report primary
utcome criteria for both treatment groups, as previ-
usly defined. The definition of clinical success for both
arotid interventions includes the absence of periproce-
ural stroke, death and MI and ipsilateral stroke as the
esult of carotid stenosis-related treatment, patch or
tent infection or thrombosis, failure of device integrity,
ncluding stent fracture or pseudoaneurysm formation.
efinitions of initial (30-day), short-term, midterm, and
ong-term clinical success and of primary, assisted pri-
ary, and secondary patency otherwise remain un-
hanged, as do recommendations for longitudinal re-
orting of clinical data. Other significant outcome
ariables, such as patch and stent integrity, quality of life,
nd cost-effectiveness can be compared with guidelines
utlined below. Likewise, grading schemes for reporting
omplications and their severity can be adapted with
able VII. Postprocedural adjunctive maneuvers
anagement of access site complications
Evacuation of hematoma
Repair of false aneurysm
Open vascular repair
Endovascular repair
anagement of postoperative stroke
Thrombolysis
Systemic administration of GP IIb/IIIa antagonists
Mechanical thrombectomy with or without thrombolysis
Balloon dilatation
Carotid endarterectomy and/or open thrombectomy
Carotid patch repair or bypass graft
anagement of lower extremity ischemia with thrombectomy,
thrombolysis, endarterectomy, patch, or bypass grafting
pen conversionittle modification for other vascular reconstructions.
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Complication Categories/Grade
Procedure-related complications
Abrupt occlusion of treated site 1. Asymptomatic. Observed, no treatment required
2. TIA or minor stroke. May require open or endovascular interventions to restore
patency
3. Major stroke or fatal outcome
Procedural bleeding 1. No need for transfusion
2. Transfusion needed; limited surgical or endovascular interventions to control
bleeding
3. Massive transfusion (3 units) and need of major open surgical intervention to
control bleeding in addition to initial vessel cutdown
Hemodynamic instability
Bradycardia
Hypotension
Hypertension
1. Temporary, hospital stay not prolonged
2. Prolonged and associated with extended hospital stay
3. Severe resulting in major neurologic or cardiac adverse events
Distal microembolization detected as new
small infarctions in brain imaging studies
1. Asymptomatic. Observed, no treatment required
2. Mild or temporary cognitive function impairment
3. Severe or persistent cognitive function impairment
Groin or cervical hematoma 1. Observed, spontaneous resolution
2. Surgical evacuation
3. Surgical arterial repair or release of nerve compression
Cranial nerve injury or palsy 1. Transient
2. Persistent but not disabling
3. Sufficiently disabling to necessitate intervention
Access site or wound infection 1. Treated with antibiotic
2. Treated with drainage
3. Required vascular reconstruction/replacement
Access site pseudoaneurysm or arteriovenous
fistula formation
1. Observed, no treatment required
2. Local treatment sufficed (compression, thrombin injection)
3. Required surgical repair
Procedural site and/or prosthetic infection
Early (30 days)/late (30 days)
Culture positive/negative
Noninvasive (exposed)
Invasive (involves prosthetic or suture line)
1. Resolved with oral antibiotics
2. Operative drainage, intravenous antibiotics
3. Major debridement, artery repair with prosthetic removal
Failed carotid intervention with or without
conversion
Device malfunction 1. No complications from attempted procedure, hospital stay not prolonged after
repair
2. Conversion to open or endovascular repair, no permanent disability
3. Significant permanent disability that impairs employment, function, or ability to
live independently or death
Arterial dissection (within 30 days of carotid
intervention)
1. Incidentally noted, asymptomatic
2. Resolved with endovascular repair
3. Open repair or fatal
Arterial perforation or rupture 1. Spontaneous closure
2. Endovascular or limited cervical carotid repair at primary procedure
3. Laparotomy/thoracotomy
Arterial elongation/kinking 1. Incidentally noted, non-flow limiting, observed, no treatment
2. Local treatment including stenting or revision and local resection
3. Occlusion resulting in stroke or need for redo open repair
Peripheral embolization 1. Resolution with intraoperative embolectomy at primary procedure
2. Embolectomy or other minor secondary operation; minor amputation
3. Arterial bypass or major arterial repair, major limb loss
Access site lymphocele, lymphorrhea,
lymphedema
1. Resolution with or without aspiration, minor edema easily controlled with elastic
support
2. Open drainage or repair
3. Permanent debilitating edema
Patch/stent complications
Dilation/aneurysm
Residual stenosis 30%
1. Observed, no treatment
2. Endovascular repairRestenosis/fractures 3. Open repair
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Volume 53, Number 6 Timaran et al 1691Finally, in comparison of two or more patient popula-
tions treated with carotid endarterectomy and stenting,
adjusting surgical risk, particularly with respect to co-
morbid medical conditions and anatomic risk factors,
must be performed according to the established high-
risk criteria for carotid interventions (Table II). The
mere reporting of outcome data for both carotid endar-
terectomy and stenting, without adequate risk-stratifica-
tion, is unacceptable. This is particularly true considering
that, since its inception, carotid stenting has been re-
served primarily as an alternative for the treatment of
patients at high-risk for carotid endarterectomy.64 Strat-
ified analyses based on anatomic or comorbid high-risk
criteria are also recommended.
REPORTING DEATHS AND COMPLICATIONS
Death. All deaths of patients undergoing carotid in-
terventions should be reported, particularly those occur-
ring during the periprocedural period, whether these are
directly related to the intervention or associated to unre-
lated conditions. All possible efforts should be made to
report the specific cause of death using information from
death certificates or autopsy examinations.
Stroke and other neurological complications.
Stroke or cerebrovascular accident is defined as a cerebral
infarction that manifests as sudden onset of focal neuro-
logical deficits that persists for more than 24 hours.9 In
those instances in which a new cerebral infraction is
demonstrated on conventional brain imaging studies, ie,
CT or MRI, the occurrence of stroke should be docu-
mented even if the symptoms last 24 hours. Stroke
severity should be determined according to validated
standardized stroke assessment scales, which should be
obtained by trained and certified personnel. The Na-
tional Institutes of Health Stroke Scale (NIHSS), Mod-
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ollow-up, particularly when the results of clinical trials
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24-hours’ duration with focal signs and symptoms that
occur after a previous stroke. The occurrence of a stroke
can be confirmed by either a one-point increase on the
NIHSS or an appropriate new or extended abnormality
seen on CT or MRI. A minor stroke is a new neurologic
event that persists for more than 24 hours but completely
resolves or returns to baseline within 30 days and
changes the NIHSS by 2 to 3 points. A major stroke is a
new neurologic event that persists after 3 days and
changes the NIHSS by at least 4 points. An ipsilateral
stroke is a stroke affecting the cerebral hemisphere sup-
plied by the treated carotid artery.68
Myocardial infarction. The periprocedural occur-
rence of myocardial infarction within 30 days of the
carotid intervention should always be reported and based
on either clinical history or electrocardiographic
changes, and cardiac enzymes.69 Accepted confirmatory
evidence of an MI includes the combination of either chest
pain or equivalent symptoms consistent with myocardial
ischemia or electrocardiographic evidence of ischemia, in-
cluding new ST segment depression or elevation1 mm in
two or more contiguous leads, plus a significant elevation of
cardiac enzymes (creatine kinase-MB or troponin) to a
value 2 or more times the individual clinical center’s labo-
ratory upper limit of normal.14,69 Although reporting the
occurrence of an MI based on only electrocardiographic or
enzyme criteria is not recommended to avoid confusion, if
reported, it must never be included as part of the primary
end point of any carotid intervention. Electrocardiographic
criteria include the presence of new pathologic Q waves in
2 or more contiguous leads, whereas enzyme criteria in-
clude elevation of creatine kinase-MB or troponin to 2 or
more times the upper limit of normal.68
Other complications. As with any vascular proce-
dures, complications after carotid interventions should be
reported in a systematic and standardized manner with a
description of the degrees of severity. Although assigning a
degree of severity to all complications of different methods
of treatment may be difficult, severity scales should be
provided whenever possible so adverse events can be as-
sessed and compared. The following severity scale has been
modified from the reporting standards for lower extremity isch-
emia by Rutherford et al18 http://www.jvascsurg.org/article/
PIIS0741521402923864/fulltextbib55:Mild (1) refers to a
complication that resolves spontaneously or with minimal
intervention, does not increase the hospital length of stay,
and does not cause permanent disability. Moderate (2)
refers to the need for significant intervention, prolongation
of hospitalization more than 24 hours, and at most, minor
permanent disability that does not interfere with normal
daily activity. A severe complication (3) needs major surgi-
cal, endovascular or medical intervention, may be associ-
ated with prolonged convalescence, is usually accompanied
by prolonged or permanent disability, and may result in
death.
All complications should be categorized as local vascu-
lar, local nonvascular, and systemic. Specific procedure- lelated or device-related complications should also be re-
orted when appropriate. All complications graded as
oderate (2) or severe (3) are considered major complica-
ions, and those graded as mild (1) can be consideredminor
omplications (Table VIII).
Cranial nerve injury. Temporary or permanent def-
cits secondary to injury to cranial nerves that occur as a
esult of a carotid intervention, particularly those that
ave not resolved by 30 days and 6 months after the
nitial procedure, should be reported. The particular
erve that is injured, resulting deficits, required interven-
ions, and effects on quality of life should be specified.
Quality of life and cost-effectiveness. Assessment of
ost of new technology and quality of life of treated
atients should be included in studies designed to eval-
ate outcomes of carotid interventions. Health-related
uality of life and functional status should be assessed
sing standardized tools such as the Medical Outcomes
tudy 36-item health status questionnaire (SF-36),
hich should be obtained at baseline and during follow-
p.70 Cost rather than charge data and medical resource
tilization should be recorded for the index hospitaliza-
ion and throughout the follow-up period using standard
ase report forms. These forms should include cost data
egarding any subsequent medical procedures, hospital-
zations, long-term care, and outpatient care required
hroughout the follow-up period. In addition, hospital
ills and billing statements could be obtained for each
ndex hospitalization. Computer-simulation models may
lso be developed using cost and quality of life data to
erform formal cost-effectiveness analyses.
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